Conference Day Two: Thursday, March 20, 2024

8:00 am Registration & Coffee

8:30 am Chair’s Opening Remarks

8:45 am Industry Leader’s Annual Briefing: Reviewing the Future of Innate Killer Research &Setting Performance Goals for 2024 & Beyond

  • Jesse Cotari Co-founder & Chief Scientific Officer, ImmuneBridge
  • Kanya Rajangam Chief Medical Officer & Head of Research & Development, Senti Biosciences Inc.
  • Raphaël OGNAR CEO, NKILT Therapeutics
  • Wei Li Chief Scientific Officer, Cytovia Therapeutics

Synopsis

Download the full event guide to find out more on session details

9:15 am Off-The-Shelf CD70-Targeting CAR NK Cells: Preclinical and Early Clinical Updates

Synopsis

Download the full event guide to find out more on session details

9:45 am Expertise Partner Presentation: PBS Biotech

10:15 am Clinical Data of AFM13 + NK cells, An Outlook of the New Study by Affimed

  • Joachim Koch Vice President and Head Discovery Research and Translational Immunology, Affimed GmbH

Synopsis

Download the full event guide to find out more on session details

10:45 am Morning Refreshments & Networking

Preclinical

Exploring the Potential of Next-Generation NK Cell Processes for Enhanced Therapeutic Functionality

11:45 am Developing MAGE-A4 specific TCR-NK cells for the treatment of solid tumors: combining optimized target specific TCR and innate killing potency

Synopsis

Download the full event guide to find out more on session details

12:15 pm Optimal Donor and Recipient Selection Strategies for Smooth Transfer into the Clinic

  • Evren Alici Co-Director of Next Generation NK Cell Competence Center, Karolinska Institutet
  • Sunil Acharya Postdoctoral Fellow, MD Anderson Cancer Center
  • Anthony Conway Head of Cell Therapy, Replay
  • Nina Horowitz Head of Research - NK Therapeutics, ImmuneBridge

Synopsis

Download the full event guide to find out more on session details

Clinical Translation

Precision Dosing Strategies for Patient Safety & Optimal Therapeutic Efficacy

11:45 am Clinical Activity Of GAIA-102 Against Refractory/ Relapsed Pediatric Solid Tumors: Data from The Single Agent Cohort in A Clinical Trial

Synopsis

Download the full event guide to find out more on session details

12:15 pm Best Practice Repeat Dosing Strategies for Accurate Data Production

  • Mini Bharathan Senior Vice President - Translational Medicine, Research & Development, Arovella Therapeutics
  • Peter Hovstadius Chief Medical Officer, XNK Therapeutics
  • Mark Exley Founder, Senior Advisor & SAB Chair, MiNK Therapeutics
  • Yu Qian Associate Director - CMC, & Cell Therapies, Takeda Pharmaceutical Co. Ltd.

Synopsis

Download the full event guide to find out more on session details

CMC & Process Development

Enhancing Quality & Cell Fitness Through Efficient Scalable Protocol Development

11:45 am Developing A GMP Compliant Manufacturing Process for Allogeneic CAR-NKT Cell Therapy Products Derived from Cord Blood

  • QI WEI SVP, Head of Technical Operations, Appia Bio

Synopsis

Download the full event guide to find out more on session details

12:15 pm Setting the Gold Standard for Sourcing NK Cells for Scalable Protocols

  • Xavier Michelet Director, Senior Investigator, Head of Pharmacology & Biology, AI Proteins
  • Jan Spanholtz CSO, Glycostem
  • Colleen Delaney Scientific Founder, Chief Scientific Officer and Executive VP of R&D, Deverra Therapeutics
  • James Li Senior Director - Research & Development, Legend Biotech

Synopsis

Download the full event guide to find out more on session details

12:45 pm Lunch Break & Networking

Exploring the Potential of Next-Generation NK Cell Processes for Enhanced Therapeutic Functionality

1:45 pm Development of Drug Resistant NK cells

  • Dan Kaufman Director & Professor - Cell Therapy & Program, University of California San Diego / Shoreline Biosciences

Synopsis

Download the full event guide to find out more on session details

2:15 pm Validation of CIR-NK Cells Against HLAG-Positive Human Tumors

  • Henri Bayle Chief Technology Officer, Chief Development Officer, NKILT Therapeutics

Synopsis

Download the full event guide to find out more on session details

2:45 pm Advancing Pre-Clinical NK Cell Therapies and Engagers: Navigating Tomorrow’s Landscape

Synopsis

Download the full event guide to find out more on session details

Constructing Robust Clinical Evaluation Strategies to Inform Enhanced Clinical Outcomes

1:45 pm How to Use NK Cells to Modulate the Whole Immune System

Synopsis

Download the full event guide to find out more on session details

2:15 pm Allogeneic Invariant NKT Cells, a Novel Platform for Cell-Based Therapies

  • Mark Exley Founder, Senior Advisor & SAB Chair, MiNK Therapeutics

Synopsis

Download the full event guide to find out more on session details

2:45 pm Advancing NK Cell Therapies and Engagers in the Clinic: Navigating Tomorrow’s Landscape

Synopsis

Download the full event guide to find out more on session details

Enhancing Quality and Cell Fitness Through Efficient Protocol Development

1:45 pm Achieving Equipotent Cryopreserved Natural Killer Cell Products

  • Neil Sheppard Principal Investigator, University of Pennsylvania - Center for Cellular Immunotherapy

Synopsis

Download the full event guide to find out more on session details

2:15 pm ImmuneBridge’s Proprietary Expansion Technology

Synopsis

Download the full event guide to find out more on session details

2:45 pm Advancing CMC & Process Development for NK Cell Therapies and Engagers: Navigating the Future

Synopsis

Download the full event guide to find out more on session details

3:00 pm Close of Summit